Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now

Amgen Inc. (NASDAQ:AMGN) is one of the top large cap value stocks to buy now. On June 7, Amgen presented new Phase 3 data ...
Fierce Pharma

ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree

As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the ...
MSN on MSN

Amgen eyes 2026 'springboard' as growth drugs offset patent pressure

Key Points Interested in Amgen Inc.? Here are five stocks we like better. Amgen said its strong first-quarter results support ...

AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS

Amgen (NASDAQ:AMGN) today announced new data at the American Diabetes Association (ADA) 86th Scientific Sessions reinforcing its commitment to addressing unmet needs for people living with ...

ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly

"ADA26: T1 and T2 diabetes readouts from Roche, MannKind and Lilly" was originally created and published by Clinical Trials ...
KXAN

AMGEN MAKES REPATHA® AVAILABLE THROUGH AMGENNOW, A DIRECT-TO-PATIENT PROGRAM IN THE U.S.

THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha ® (evolocumab). This follows ...
Health Affairs

Amgen’s Retreat: Denmark, Repatha, And The Collision Course Of US MFN Pricing Policy

Repatha is not a drug where Amgen has pricing power to absorb such exposure. The Denmark exit should be read as a rational, if disruptive, response to that specific vulnerability — not as the ...
Nasdaq

Amgen's Repatha, Evenity & Blincyto Drive Sales This Earnings Season

Amgen AMGN delivered yet another strong quarterly performance. Its second-quarter 2025 earnings and sales beat estimates. The company has been recording consistently strong top-line performance. Amgen ...